| Complete Publications in PubMed:
| ADULT INFECTIOUS DISEASE FACULTY |
Robert F. Betts, MD
William Bonnez, MD
Susan Cohn, MD, MPH
Lisa M. Demeter, MD
Ghinwa Dumyati, MD
Carrie Dykes, PhD
Ann R. Falsey, MD
Steven Fine, MD, PhD
|
Paul S. Graman, MD
Christine M. Hay, MD
Xia Jin, MD, PhD
Michael C. Keefer, MD
Christine Koval, MD
Amneris Luque, MD
Peter Mariuz, MD
Richard C. Reichman, MD |
Robert Rose, PhD
Jacob Schlesinger, MD
Mark Shelly, MD
John Treanor, MD
Marguerite Urban, MD
Edward Walsh, MD |
| PEDIATRIC INFECTIOUS DISEASE FACULTY |
Mary Caserta, MD
Cynthia Christy, MD
Francis Gigliotti, MD
Caroline Hall, MD
Geoffrey Weinberg, MD
Melanie Wellington, MD |
Selected Publications: 1998 - 2006
(alphabetical by first author) Anderson P, Treanor J, Porcelli S, Pichichero M. Non-interference between two protein carriers when used with the same polysaccharide for pneumococcal conjugate vaccines in 2-year-old children. Vaccine 2003;21:1554-9. Anolik JH. Wildy K. Cohn SE. et al. Multifocal Staphylococcus aureus infection originating from the sacroiliac joint in a patient with rheumatoid arthritis. J Rheum 2001;28(1):217-20. Archer RH, Gerondelis P, Dykes C, Fox K, Fay P, Reichman RC, Bambara RA, Demeter LM. Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture. J Virol 2000;74:8390-8401. Archer RH. Wisniewski M. Bambara RA. Demeter LM. The Y181C mutant of HIV-1 reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors alters the size distribution of RNase H cleavages. Biochemistry 2001;40(13):4087-95. Bates DW, Yu DT, Black E, Sands K, Schwartz JS, Hibberd PL, Graman PS, Lanken PN, Kahn KL, Snydman DR, Parsonnet J, Moore R, Platt R. Resource utilization among patients with sepsis syndrome. Infect Control Hosp Epidemiol 2003;24(1):62-70. Bates DW. Parsonnet J. Ketchum PA. Miller EB. Novitsky TJ. Sands K. Hibberd PL. Graman PS, et al. Limulus amebocyte lysate assay for detection of endotoxin in patients with sepsis syndrome. AMCC Sepsis Project Working Group. Clin Infect Dis 1998;27(3):582-91. Belshe RB, Newman FK, Frey SE, Couch RB, Treanor JJ, Tacket CO, Yan L. Dose-dependent neutralizing-antibody responses to vaccinia. J Infect Dis 2004;189:493-7. Belshe RB. Gorse GJ. Mulligan MJ. Evans TG. Keefer MC, et al. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS 1998;12(18):2407-15. Belshe RB. Gruber WC. Mendelman PM. Cho I. Reisinger K. Block SL. Wittes J. Iacuzio D. Piedra P. Treanor J, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatrics. 2000;136(2):168-75. Belshe RB. Gruber WC. Mendelman PM. Mehta HB. Mahmood K. Reisinger K. Treanor J, et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000;181:1133-7. Belshe RB. Mendelman PM. Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998;338(20):1405-12. Belshe RB. Stevens C. Gorse GJ. Buchbinder S. Weinhold K. Sheppard H. Stablein D. Self S. McNamara J. Frey S. Flores J. Excler JL. Klein M. Habib RE. Duliege AM. Harro C. Corey L. Keefer M. Mulligan M. et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J Infect Dis 2001;183(9):1343-52. Benson CA. Williams PL. Cohn DL. Becker S. Hojczyk P. Nevin T. Korvick JA. Heifets L. Child CC. Lederman MM. Reichman RC, et al. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. J Infect Dis 2000;181(4):1289-97. Berger AA. Anekthananon T. Bonnez W. Evans T. Photo quiz. Chronic cutaneous verrucous varicella-zoster infection. Clin Infect Dis 1998;27(2):259, 380-1. Bernstein DI. Yan L. Treanor J. Mendelman PM. Belshe R. Cold-Adapted, Trivalent, Influenza Vaccine Study Group. Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children. Ped Infect Dis J. 2003;22(1):28-34. Betts RF. Treanor JJ. Approaches to improved influenza vaccination. Vaccine 2000;18(16):1690-5. Bonnez W. DaRin C. Borkhuis C. de Mesy Jensen K. Reichman RC. Rose RC. Isolation and propagation of human papillomavirus type 16 in human xenografts implanted in the severe combined immunodeficiency mouse. J Virology 1998;72(6):5256-61. Bonnez W. Editorial comment: issues with HIV and oral human papillomavirus infections. AIDS Read. 2002;12(4):174-6. Bonnez W. The 18th International Papillomavirus Conference. Antivir Ther. 2000;5(4):279-83. Bonnez W. The 19th International Papillomavirus Conference. Antivir Ther. 2002;7(1):67-72.
Bonnez W. A comment on "Butcher's warts: dermatological heritage or testable misinformation?". Arch Dermatology. 2002;138(3):411. Bonnez W. Editorial comment: issues with HIV and oral human papillomavirus infections. AIDS Reader. 2002;12(4):174-6. Brander C, Yang OO, Jones NG, Lee Y, Goulder P, Johnson RP, Trocha A, Colbert D, Hay C, Buchbinder S, Bergmann CC, Zweerink HJ, Wolinsky S, Blattner WA, Kalams SA, Walker BD. Efficient processing of the immunodominant, HLA-A*0201-restricted human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitope despite multiple variations in the epitope flanking sequences. J Virol. 1999;73(12):10191-8. Brooks AM, McBride JT, McConnochie KM, Aviram M, Long C, Hall CB. Predicting deterioration in previously healthy infants hospitalized with respiratory syncytial virus infection. Pediatrics. 1999;104(3 Pt 1):463-7. Bruckner L, Gigliotti F. Alpha-hemolytic streptococcal infections among immunocompromised hosts: increasing incidence, severity and antibiotic resistance. Pediatr Infect Dis J. 2002;21(4):343-5 Bruckner LB, Korones DN, Karnauchow T, Hardy DJ, Gigliotti F. High incidence of penicillin resistance among alpha-hemolytic streptococci isolated from the blood of children with cancer. J Pediatr. 2002;140(1):20-6. Caserta MT, Hall CB, Schnabel K, Long CE, D'Heron N. Primary human herpesvirus 7 infection: a comparison of human herpesvirus 7 and human herpesvirus 6 infections in children. J Pediatr. 1998;133(3):386-9. Caserta MT, Hall CB. A practitioner's guide to human herpesvirus-6 (HHV-6) and human herpesvirus-7 (HHV-7). AIDS Patient Care STDS. 1998;12(11):833-42. Caserta MT, Hall CB. Antiviral agents for influenza. Pediatr Ann. 2000;29(11):704-11. Caserta MT, Mock DJ, Dewhurst S. Human herpesvirus 6. Clin Infect Dis. 2001;33(6):829-33. Caserta MT. Human Herpesvirus 6 Infection of the Central Nervous System. Curr Infect Dis Rep. 2004;6(4):316-321. Casiano-Colon AE, Hulbert BB, Mayer TK, Walsh EE, Falsey AR.Insensitivity of rapid antigen tests for the diagnosis of respiratorysyncytial virus in adults. J Clin Virol 2003;14:56.
Chadha KC, Schwartz SA, Nair MP, Demeter LM, Hewitt RG. Serum interferon inhibitor declines in patients with HIV-1 infection after a change in antiretroviral therapy. Immunol Invest. 2003;32(4):299-312.
Chamat S. Walsh EE. Anderson D, et al.. Human monoclonal antibodies isolated from spontaneous Epstein-Barr virus-transformed tumors of Hu-SPL-SCID mice and specific for fusion protein display broad neutralizing activity toward respiratory syncytial virus. J Infect Dis 1999;180(2):268-77. Chambers TJ. Liang Y. Droll DA. Schlesinger JJ. Davidson AD. Wright PJ. Jiang X. Yellow fever virus/dengue-2 virus and yellow fever virus/dengue-4 virus chimeras: biological characterization, immunogenicity, and protection against dengue encephalitis in the mouse model. J Virology. 2003;77(6):3655-68.
Chen HY, Reichman R, Keefer M, McDermott MPand Jin X. Establishment of an Alternative Intracellular Cytokine Staining Assay for HIV/AIDS Clinical Studies. Journal of Virological Methods 2005, 123:131-140. Chen S, Weinberg GA. Acute retinal necrosis syndrome in a child. Pediatr Infect Dis J. 2002;21(1):78-80.Christy C, Aligne CA, Auinger P, Pulcino T, Weitzman M. Effectiveness of influenza vaccine for the prevention of asthma exacerbations. Arch Dis Child. 2004;89(8):734-5.Christy C. Foodborne diseases: fruits and vegetables. Pediatr Infect Dis J. 1999;18(10):911-2.
Clark HF, Bernstein DI, Dennehy PH, Offit P, Pichichero M, Treanor J, Ward RL, Krah DL, Shaw AR, Dallas MJ, Eiden JJ, Ivanoff N, Kaplan KM, Heaton P. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J Pediatr 2004;144(2):184-90. Clark RA. Cohn SE. Jarek C, et al. Perimenopausal symptomatology among HIV-infected women at least 40 years of age. J AIDS 2000;23(1):99-100. Clements-Mann ML. Weinhold K. Matthews TJ. Graham BS. Gorse GJ. Keefer MC, et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis 1998;177(5):1230-46.
Cohn SE, Clark RA. Sexually Transmitted diseases, HIV, and AIDS in women. Med Clin N Am 2003;87(5):971-95
Cohn S, Hitti J. Issues regarding use of hormonal contraceptives in clinical trials of antiretroviral therapy. J Acquir Immune Defic Syndr. 2005; Suppl 1:S21-2.
Cohn SE. Kammann E. Williams P. Currier JS. Chesney MA. Association of adherence to Mycobacterium avium complex prophylaxis and antiretroviral therapy with clinical outcomes in Acquired Immunodeficiency Syndrome. Clin Infect Dis. 2002;34(8):1129-36.
Cohn SE. Women With HIV/AIDS: Treating the Fastest Growing Population. Editorial. AIDS Reader 2003; May:241-244
Cohn SE, Berk ML, Berry SH, et al. The care of HIV-infected adults in rural areas of the United States. J Acquir Immune Defic Syndr. 2001;28(4):385-92
Coughlin RT. White AC. Anderson CA. Carlone GM. Klein DL. Treanor J. Characterization of pneumococcal specific antibodies in healthy unvaccinated adults. Vaccine. 1998;16(18):1761-7. Coury-Doniger P. Levenkron JC. Knox KL. Cowell S. Urban MA. Use of stage of change (SOC) to develop an STD/HIV behavioral intervention: phase 1. A system to classify SOC for STD/HIV sexual risk behaviors--development and reliability in an STD clinic. AIDS Patient Care & STDS 1999;13(8):493-502. Currier JS. Williams PL. Koletar SL. Cohn SE. et al. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000;133(7):493-503. D'Aquila RT. Schapiro JM. Brun-Vezinet F. Clotet B. Conway B. Demeter LM. Grant RM. Johnson VA. Kuritzkes DR. Loveday C. Shafer RW. Richman DD. Drug resistance mutations in HIV-1. Topics in HIV Medicine. 2003;11(3):92-6.
de Bruyn G, Rossini AJ, Chiu YL, Holman D, Elizaga ML, Frey SE, Burke D, Evans TG, Corey L, Keefer MC. Safety profile of recombinant canarypox HIV vaccines. Vaccine. 2004;22(5-6):704-13.
Demeter L. Haubrich R. International perspectives on antiretroviral resistance. Phenotypic and genotypic resistance assays: methodology, reliability, and interpretations. J AIDS 2000;26 Suppl 1:S3-9. Demeter LM, Erice A, Ribaudo HJ, Eshleman SH, Hammer SM, Hellmann N, Fischl MA. Antiretroviral resistance in subjects with advanced HIV-1 infection failing combination therapy with three and four antiretrovirals. Clin Infect Dis 2004;39:552-8. Demeter LM, Hughes MD, Coombs RW, Jackson JB, Grimes J, Bosch RJ, Fiscus S, Spector S, Bremer J, Erice A, Johnson V, Cook J, Squires KM, Fischl MA, Hammer SM. Predictors of virologic and clinical responses in HIV-1 infected patients receiving indinavir, zidovudine and lamivudine (AIDS Clinical Trials Group Protocol 320). Ann Internl Med 2001;135:954-64. Demeter LM, Ribaudo HJ, Erice A, Eshleman SH, Hammer SM, Hellmann NS, Fischl MA; AIDS Clinical Trials Group Protocol 388. HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388. Clin Infect Dis. 2004;39(4):552-8.
Demeter LM. Bosch RJ. Coombs RW. Fiscus S. Bremer J. Johnson VA. Erice A. Jackson JB. Spector SA. Squires KM. Fischl MA. Hughes MD. Hammer SM. Detection of replication-competent human immunodeficiency virus type 1 (HIV-1) in cultures from patients with levels of HIV-1 RNA in plasma suppressed to less than 500 or 50 copies per milliliter. J Clin Microbiol. 2002;40(6):2089-94 Demeter LM. D'Aquila R. Weislow O, et al. Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. ACTG Sequencing Working Group. AIDS Clinical Trials Group. J Virological Methods. 1998;75(1):93-104. Demeter LM. Meehan PM. Morse G. Fischl MA. Para M. Powderly W. Leedom J. Holden-Wiltse J. Greisberger C. Wood K. Timpone J Jr. Wathen LK. Nevin T. Resnick L. Batts DH. Reichman RC. Phase I study of atevirdine mesylate (U-87201E) monotherapy in HIV-1-infected patients. J AIDS. 1998;19(2):135-44. Demeter LM. Shafer RW. Meehan PM. Holden-Wiltse J. Fischl MA. Freimuth WW. Para MF. Reichman RC. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Antimicrob Agents Chemother. 2000;44(3):794-7. DiCenzo R, Shelton M, Jordan K, Koval C, Forrest A, Reichman R, Morse G. Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy. 2003;23(7):866-70.
DiCenzo R, Luque AE, Larppanichpoonphol P, Reichman RC. Association of total billirubin with indinavir and lopinavir plasma concentrations in HIV-infected patients receiving three different double-boosted dosing regimens. J Antimicrob Chemother. 2006 Aug;58(2):393-400.
Domaoal RA, Demeter LM. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors. Int J Biochem Cell Biol 2004;36(9):1735-51. Dreyer K. Kallas EG. Planelles V. Montefiori D. McDermott MP. Hasan MS. Evans TG. Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy. AIDS Res Human Retroviruses 1999;15(17):1563-71. Dumyati G. Falsey AR. Antivirals for influenza: what is their role in the older patient? Drugs & Aging. 2002;19(10):777-86. Dyer WB. Ogg GS. Demoitie MA. Jin X. et al. Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with nef-defective HIV type 1. J Virology 1999;73(1):436-43.
Dykes C, Wang J, Jin X, Vicente Planelles, Dong Sung An, Amanda Tallo, Yangxin Huang, Hulin Wu and Demeter LM. Evaluation of a Multiple-Cycle, Recombinant Virus, Growth Competition Assay that Uses Flow Cytometry to Measure Replication Efficiency of HIV-1 in Cell Culture. Journal of Clinical Microbiology 2006: 1930-1943.
Dykes C, Balakrishnan M, Planelles V, Zhu Y, Bambara RA, Demeter LM. Identification of a preferred region for recombination and mutation in HIV-1 gag. Virology 2004;326(2):262-79.
Dykes C, Mootsikapun P, Dexter A, Chiulli M, Berrios L, Reichman RC, Demeter LM. Analysis of env sequence evolution in HIV-infected patients receiving therapy with non-nucleoside reverse transcriptase inhibitors. J Infect Dis 2000;182:316-20. Dykes C, Najjar J, Bosch R, Wantman M, Furtado M, Hart S, Hammer S, Demeter LM. Detection of minority drug-resistant variants of HIV-1 during virologic failure of zidovudine, lamivudine and indinavir. J Infect Dis 2004;189:1091-6. Dykes C. Fox K. Lloyd A. Chiulli M. Morse E. Demeter LM. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants. Virology. 2001;285(2):193-203. Dykes, C, Balakrishnan M, Planelles V, Fox K, Bambara RA, Demeter LM. Identification of a preferred region for recombination in HIV-1 gag. Virology 2004;326:262-79. El-Daher N. Magnussen R. Betts RF. Varicella pneumonitis: clinical presentation and experience with acyclovir treatment in immunocompetent adults. Internat J Infect Dis 1998;2(3):147-51. Elhassan NO, Stevens TP, Gigliotti F, Hardy DJ, Cole CA, Sinkin RA. Vancomycin usage in central venous catheters in a neonatal intensive care unit. Pediatr Infect Dis J. 2004;23(3):201-6. Elhassan NO, Stevens TP, Sorbero ME, Dick AW, Guillet R, Hall CB. Guidelines for palivizumab prophylaxis: are they based on infant's risk ofhospitalization for respiratory syncytial viral disease? Pediatr Infect Dis J. 2003;22(11):939-43. Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, Suzich JA, O'Brien D, Campbell M, White WI, Balsley J, Reichman RC. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis. 2001;183(10):1485-93. Evans TG, Bonnez W, Soucier HR, Fitzgerald T, Gibbons DC, Reichman RC. Highly active antiretroviral therapy results in a decrease in CD8+ T cell activation and preferential reconstitution of the peripheral CD4+ T cell population with memory rather than naive cells. Antiviral Res. 1998;39(3):163-73. Evans TG. Fitzgerald T. Gibbons DC. Keefer MC. Soucier H. Th1/Th2 cytokine responses following HIV-1 immunization in seronegative volunteers. The AIDS Vaccine Evaluation Group. Clin Experimental Immunol 1998;111(2):243-50. Evans TG. Kallas EG. Luque AE. Menegus M. McNair C. Looney RJ. Expansion of the CD57 subset of CD8 T cells in HIV-1 infection is related to CMV serostatus. AIDS 1999;13(9):1139-41. Evans TG. Keefer MC. Weinhold KJ, et al. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis 1999;180(2):290-8. Evans TG. McElrath MJ. Matthews T. Montefiori D. Weinhold K. Wolff M. Keefer MC. et al. NIAID AIDS Vaccine Evaluation Group. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine 2001;19(15-16):2080-91. Falsey AR, Formica MA, Treanor JJ, Walsh EE. Comparison of quantitative reverse transcription-PCR to viral culture for assessment of respiratory syncytial virus shedding. J Clin Microbiol 2003;41:4160-5. Falsey AR, Formica MA, Walsh EE. Diagnosis of respiratory syncytial virus: comparison of reverse transcription polymerase chain reaction (RT-PCR) to viral culture and serology in adults with respiratory illness. J Clin Microbiol 2002;40(3): 817-820. Falsey AR, Walsh EE, Hayden FG. Rhinovirus and coronavirus infection-associated hospitalization among older adults. J Infect Dis 2002;185:1338-1341. Falsey AR. Criddle MM. Kolassa JE. McCann RM. Brower CA. Hall WJ. Evaluation of a handwashing intervention to reduce respiratory illness rates in senior day-care centers. Infect Control Hosp Epidemiol 1999;20(3):200-2. Falsey AR. Respiratory syncytial virus infection in older persons. Vaccine 1998;16(18):1775-8. Falsey AR. Walsh EE. Francis CW. Looney RJ. Kolassa JE. Hall WJ. Abraham GN. Response of C-reactive protein and serum amyloid A to influenza A infection in older adults. J Infect Dis 2001;183(7):995-9. Falsey AR. Walsh EE. Looney RJ. Kolassa JE. Formica MA. Criddle MC. Hall WJ. Comparison of respiratory syncytial virus humoral immunity and response to infection in young and elderly adults. J Med Virology 1999;59(2):221-6. Falsey AR. Walsh EE. Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. J Infect Dis 1998;177(2):463-6. Falsey AR. Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiology Rev 2000;13(3):371-84l. Falsey AR. Erdman D. Anderson LJ. Walsh EE. Human metapneumovirus infections in young and elderly adults. J Infect Dis. 2003;187(5):785-90. Falsey AR. Walsh EE. Hayden FG. Rhinovirus and coronavirus infection-associated hospitalizations among older adults. J Infect Dis. 2002;185(9):1338-41. Falsey AR. Walsh EE. Novel coronavirus and severe acute respiratory syndrome. Lancet. 2003;361(9366):1312-3. Fichtenbaum CJ. Koletar S. Yiannoutsos C. Holland F. Pottage J. Cohn SE. et al. Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clin Infect Dis 2000;30(5):749-56. Fine SM. Maggirwar SB. Elliott PR. Epstein LG. Gelbard HA. Dewhurst S. Proteasome blockers inhibit TNF-alpha release by lipopolysaccharide stimulated macrophages and microglia: implications for HIV-1 dementia. J Neuroimmunol 1999;95:55-64. Frankel MR. Shapiro MF. Duan N. Morton SC. Berry SH. Brown JA. Burnam MA. Cohn SE, et al. National probability samples in studies of low-prevalence diseases. Part II: Designing and implementing the HIV cost and services utilization study sample. Health Serv Res 1999;34(5 Pt 1):969-92. Frey SE. Couch RB. Tacket CO. Treanor JJ. Wolff M. Newman FK. Atmar RL. Edelman R. Nolan CM. Belshe RB. Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med. 2002;346(17):1265-74. Gerondelis P. Archer RH. Palaniappan C. Reichman RC. Fay PJ. Bambara RA. Demeter LM. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities. J Virology. 1999;73(7):5803-13. Gigliotti F, Haidaris CG, Wright TW, Harmsen AG. Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia. Infect Immun. 2002;70(3):1069-74. Gigliotti F, Harmsen AG, Wright TW. Characterization of transmission of Pneumocystis carinii f. sp. muris through immunocompetent BALB/c mice. Infect Immun. 2003;71(7):3852-6. Gigliotti F, Murante BL, Weinberg GA. Short course directly observed therapy to monitor compliance with antiretroviral therapy in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2001;20(7):716-8. Gilbert PB, Chiu YL, Allen M, Lawrence DN, Chapdu C, Israel H, Holman D, Keefer MC, Wolff M, Frey SE; NIAID HIV Vaccine Trials Network. Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials. Vaccine. 2003;21(21-22):2933-47. Gonzalez IM. Karron RA. Eichelberger M. Walsh EE. Delagarza VW. Bennett R. Chanock RM. Murphy BR. Clements-Mann ML. Falsey AR. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults. Vaccine 2000;18(17):1763-72. Graham BS. McElrath MJ. Connor RI. Schwartz DH. Gorse GJ. Keefer MC, et al. Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. J Infect Dis 1998;177(2):310-9. Griggs JJ. Blair EA. Norton JR. Rowe JM. Flesher WR. Betts RF. Ciprofloxacin plus piperacillin is an equally effective regimen for empiric therapy in febrile neutropenic patients compared with standard therapy. Amer J Hematol 1998;58(4):293-7. Guerra CE. Betts RF. O'Keefe RJ. Shilling JW. Mycobacterium bovis osteomyelitis involving a hip arthroplasty after intravesicular bacille Calmette-Guerin for bladder cancer. Clin Infect Dis 1998;27(3):639-40.
Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA 3rd, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL, Kuritzkes DR; AIDS Clinical Trials Group Study A5095 Team. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350(18):1850-61
Gupta K. Hudgens M. Corey L. McElrath MJ. Weinhold K. Montefiori DC. Gorse GJ. Frey SE. Keefer MC. Evans TG. et al. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acq Imm Defic Syndr: JAIDS. 2002;29(3):254-61. Hall CB, Caserta MT, Schnabel KC, Long C, Epstein LG, Insel RA, Dewhurst S. Persistence of human herpesvirus 6 according to site and variant: possible greater neurotropism of variant A. Clin Infect Dis. 1998;26(1):132-7. Hall CB, Long CE, Schnabel KC. Respiratory syncytial virus infections in previously healthy working adults. Clin Infect Dis. 2001;33(6):792-6. Hall CB, Stevens TP, Swantz RJ, Sinkin RA, McBride JT. Development of local guidelines for prevention of respiratory syncytial viral infections. Pediatr Infect Dis J. 1999;18(10):850-3. Hall CB. Diagnosis and testing in bronchiolitis: a systematic review. J Pediatr. 2004;145(3):417-8. Hall CB. Nosocomial respiratory syncytial virus infections: the "Cold War" has not ended. Clin Infect Dis. 2000;31(2):590-6. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344(25):1917-28. Halperin SA. Smith B. Mabrouk T. Germain M. Trepanier P. Hassell T. Treanor J. Gauthier R. Mills EL. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine. 2002;20(7-8):1240-7.
Hammer SM, Bassett R, Squires KE, Fischl MA, Demeter LM, Currier JS, Mellors JW, Morse GD, Eron JJ, Santana JL, DeGruttola V; ACTG 372B/D Study Team. A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir. Antivir Ther. 2003;8(6):507-18.
Hasan MS. Agosti JM. Reynolds KK. Tanzman E. Treanor JJ. Evans TG. Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination of healthy adults. J Infect Dis 1999;180(6):2023-6. Hashem M, Hall CB. Respiratory syncytial virus in healthy adults: the cost of a cold. J Clin Virol. 2003;27(1):14-21. Hay C, Rosenberg E. Immunologic response to HIV. AIDS Clin Care. 1998;10(1):1-3.
Hay CM. Ruhl DJ. Basgoz NO. Wilson CC. Billingsley JM. DePasquale MP. D'Aquila RT. Wolinsky SM. Crawford JM. Montefiori DC. Walker BD. Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection. J Virology. 1999; 73(7):5509-19. Hayden FG. Treanor JJ. Fritz RS. Lobo M. Betts RF, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA. 1999;282(13):1240-6. Hirsch MS. Brun-Vezinet F. Clotet B. Conway B. Kuritzkes DR. D'Aquila RT. Demeter LM. Hammer SM. Johnson VA. Loveday C. Mellors JW. Jacobsen DM. Richman DD. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2003;37(1):113-28. Hirsch MS. Brun-Vezinet F. Clotet B. Conway B. Kuritzkes DR. D'Aquila RT. Demeter LM. Hammer SM. Johnson VA. Loveday C. Mellors JW. Richman DD. Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines Panel. Topics in HIV Medicine 2003;11(4):150-4. Hirsch MS. Brun-Vezinet F. D'Aquila RT. Hammer SM. Johnson VA. Kuritzkes DR. Loveday C. Mellors JW. Clotet B. Conway B. Demeter LM. et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA. 2000;283(18):2417-26. Hirsch MS. Conway B. D'Aquila RT. Johnson VA. Brun-Vezinet F. Clotet B. Demeter LM, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. JAMA. 1998;279(24):1984-91. Horan JT. Francis CW. Falsey AR. Kolassa J. Smith BH. Hall WJ. Prothrombotic changes in hemostatic parameters and C-reactive protein in the elderly with winter acute respiratory tract infections. Thrombosis Haemostasis 2001;85(2):245-9.
Islam SA, Hay CM, Hartman KE, He S, Shea AK, Trocha AK, Dynan MJ, Reshamwala N, Buchbinder SP, Basgoz NO, Kalams SA. Persistence of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte clones in a subject with rapid disease progression. J Virol. 2001;75(10):4907-11.
Ison MG, Gnann J, Nagy-Agren S, Treanor J, Paya C, Steigbigel R, Elliott M, Weiss HL, Hayden FG. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antiviral Ther 2003;8:183-90.
Iwane MK, Edwards KM, Szilagyi PG, Walker FJ, Griffin MR, Weinberg GA, Coulen C, Poehling KA, Shone LP, Balter S, Hall CB, Erdman DD, Wooten K, Schwartz B; New Vaccine Surveillance Network. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics. 2004;113(6):1758-64.
Jackson JB, Piwowar-Manning EM, Johnson-Lewis L, Bassett R, Demeter L, Brambilla DJ. Comparison of versions 1.0 and 1.5 of the ultrasensitive AMPLICOR HIV-1 monitor test for subjects with low viral load. J Clin Microbiol 2004;42(6):2774-2776.
Jacobson JM, Pat Bucy R, Spritzler J, Saag MS, Eron JJ Jr, Coombs RW, Wang R, Fox L, Johnson VA, Cu-Uvin S, Cohn SE, et al. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068.
J Infect Dis. 2006 194(5):623-32.
Jin X. Bauer DE. Tuttleton SE. et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999;189(6):991-8. Jin X. Demoitie MA. Donahoe SM. et al. High frequency of cytomegalovirus-specific cytotoxic T-effector cells in HLA-A*0201-positive subjects during multiple viral coinfections. J Infect Dis 2000;181(1):165-75. Jin X. Ogg G. Bonhoeffer S. Safrit J. et al. An antigenic threshold for maintaining human immunodeficiency virus type 1-specific cytotoxic T lymphocytes. Molecular Medicine 2000; 6(9):803-9 Jin X. Roberts CG. Nixon DF. et al. Identification of subdominant cytotoxic T lymphocyte epitopes encoded by autologous HIV type 1 sequences, using dendritic cell stimulation and computer-driven algorithm. AIDS Research Human Retroviruses. 2000;16(1):67-76. Jin X. Roberts CG. Nixon DF. et al. Longitudinal and cross-sectional analysis of cytotoxic T lymphocyte responses and their relationship to vertical human immunodeficiency virus transmission. J Infect Dis 1999;178(5):1317-26. Jin X. Wills M. Sissons JG. Carmichael A. Progressive loss of IL-2-expandable HIV-1-specific cytotoxic T lymphocytes during asymptomatic HIV infection. European J Immunol. 1998;28(11):3564-76.
Jin X. Gao X. Ramanathan M Jr. Deschenes GR. Nelson GW. O'Brien SJ. Goedert JJ. Ho DD. O'Brien TR. Carrington M. Human immunodeficiency virus type 1 (HIV-1)-specific CD8+-T-cell responses for groups of HIV-1-infected individuals with different HLA-B*35 genotypes. J Virology. 2002 76(24):12603-10.
Jin X. Ramanathan M Jr. Barsoum S. Deschenes GR. Ba L. Binley J. Schiller D. Bauer DE. Chen DC. et al. Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy. J Virology. 2002;76(5):2206-16.
Jin X, Brooks A, Chen H, Bennett R, Reichman R and Smith H. APOBEC3G/CEM15 mRNA Levels Associates Inversely with HIV Viremia. Journal of Virology 2005, 79 (17):11516. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DD; International AIDS Society-USA Drug Resistance Mutations Group. Drug resistance mutations in HIV-1. Top HIV Med. 2003;11(6):215-21.
Jordan EF, Nye MB, Luque AE. Successful treatment of Pasteurella multocida meningitis with aztreonam.
Scand J Infect Dis. 2006;38(6-7):534-6.
Kallas EG. Gibbons DC. Soucier H. Fitzgerald T. Treanor JJ. Evans TG. Detection of intracellular antigen-specific cytokines in human T cell populations. J Infect Dis 1999;179(5):1124-31.
Kallas EG. Reynolds K. Andrews J. Fitzgerald T. Kasper M. Menegus M. Evans TG. Cytomegalovirus-specific IFNgamma and IL-4 are produced by antigen expanded human blood lymphocytes from seropositive volunteers. Immunol Lett 1998;64(2-3):63-9. Kallas EG. Reynolds K. Andrews J. Treanor JJ. Evans TG. Production of influenza-stimulated tumor necrosis factor-alpha by monocytes following acute influenza infection in humans. J Interferon Cytokine Res 1999;19(7):751-5. King JC Jr. Treanor J. Fast PE. et al. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis 2000;181(2):725-8.
Koletar SL, Williams PL, Wu J, McCutchan JA, Cohn SE, Murphy RL, Lederman HM, Currier JS. Long-term follow-up of HIV-infected individuals who have significant increases in CD4+ cell counts during antiretroviral therapy. Clin Infect Dis. 2004 39(10):1500-6.
Koval D. Gigliotti F. Nevins D. Demeter L. Immune reconstitution syndrome following successful treatment of Pneumocystis carinii pneumonia in an HIV-1 infected man. Clinical Infect Dis. 2002;35(4):491-3. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, Walsh EE, Freeman MW, Golenbock DT, Anderson LJ, Fingerg RW. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nature Med 2000;1(5): 398-401. Lambert JS. Keefer M. Mulligan MJ. et al. A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects. Vaccine 2001;19(23-24):3033-42. Landon BE. Wilson IB. Wenger NS. Cohn SE. Fichtenbaum CJ. Bozzette SA. Shapiro MF. Cleary PD. Specialty training and specialization among physicians who treat HIV/AIDS in the United States. J Gen Intern Med. 2002;17 (1):12-22. Landon BE. Wilson IB. Cohn SE. Fichtenbaum CJ. Wong MD. Wenger NS. Bozzette SA. Shapiro MF. Cleary PD. Physician specialization and antiretroviral therapy for HIV. J Gen Intern Med. 2003;18(4):233-41. Lederman HL, Williams PL, Wu J, Evans T, Cohn SE, McCutchan JA, Koletar SL, Hafner R, Connick E, Valentin FT, McElrath MJ, Hooton T, Roberts NJ., Currier JS, Incomplete Immunologic Reconstitution Following Institution of Highly Active Antiretroviral Therapy (HAART) in HIV-Infected Patients with Severe CD4 Depletion. J Infect Dis 2003;188:1793-803 Lee D, Graham BS, Chiu YL, Gilbert PB, McElrath MJ, Belshe RB, Buchbinder SP, Sheppard HW, Koblin BA, Mayer KH, Keefer MC, Mulligan MJ, Celum CL. Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160. J Infect Dis. 2004;190(5):903-7 Lee FE, Walsh EE, Falsey AR, Betts RF, Treanor JJ. Experimental infection of humans with A2 respiratory syncytial virus. Antiviral Res. 2004;63(3):191-6. Lee LH, Caserta MT. Malaria: update on treatment. Pediatr Infect Dis J. 1998;17(4):342-3. Lee LH, Gigliotti F, Wright TW, Simpson-Haidaris PJ, Weinberg GA, Haidaris CG. Molecular characterization of KEX1, a kexin-like protease in mouse Pneumocystis carinii. Gene. 2000;242(1-2):141-50. Lee LH, LeVea CM, Graman PS: Congenital tuberculosis in a neonatal intensive care unit: case report, epidemiologic investigation and management of exposures. Clin Infect Dis 1998;27:474-7..
Li L, Wei FL, Mei S, Feng X, Yao J, Jin X, Cao YZ. Virological and immunological outcomes in HIV-1-infected Chinese patients treated with a combination of Efavirenz and Indinavir for 48 weeks. Chin Med J (Engl). 2004;117(3):347-52.
Liu D, Yu J, Reichman R, Chang X, Wu H, Jin X. Statistical Determination of Threshold for Cellular Division in the CFSE-labeling Assay. Journal of Immunological Methods 2006, 312:126-136.
Looney RJ. Falsey AR. Walsh E. Campbell D. Effect of aging on cytokine production in response to respiratory syncytial virus infection. J Infect Dis. 2002;185(5):682-5. Looney RJ. Hasan MS. Coffin D. Campbell D. Falsey AR. Kolassa J. Agosti JM. Abraham GN. Evans TG. Hepatitis B immunization of healthy elderly adults: relationship between naive CD4+ T cells and primary immune response and evaluation of GM-CSF as an adjuvant. J Clin Immunol 2001;21(1):30-6. Luque AE. Demeter LM. Reichman RC. Association of human papillomavirus infection and disease with magnitude of human immunodeficiency virus type 1 (HIV-1) RNA plasma level among women with HIV-1 infection. J Infect Dis. 1999;179(6):1405-9. Luque AE. Kaminski D. Reichman R. Hardy D. Mycobacterium szulgai osteomyelitis in an AIDS patient. Scand J Infect Dis 1998;30(1):88-91.
Luque AE, Jabeen M, Messing S et al . Prevalence of human papillomavirus genotypes and related abnormalities of cervical cytological results among HIV-1-infected women in Rochester, New York. J Infect Dis. 2006;194(4):428-34.
Mabanta CG, Pryhuber GS, Weinberg GA, Phelps DL. Erythromycin for the prevention of chronic lung disease in intubated preterm infants at risk for, or colonized or infected with Ureaplasma urealyticum. Cochrane Database Syst Rev. 2003(4):CD003744.
Marais D. Rose RC. Lane C, et al. Seroresponses to virus-like particles of human papillomavirus types 16, 18, 31, 33, and 45 in San people of Southern Africa. J Med Virology 2000;60(3):331-6.
Marais DJ. Rose RC. Lane C, et al. Seroresponses to human papillomavirus types 16, 18, 31, 33, and 45 virus-like particles in South African women with cervical cancer and cervical intraepithelial neoplasia. J Med Virology 2000;60(4):403-10. Mariuz P, Steigbigel RT: Dialysis Related Infections. In: Current Therapy of Infectious Diseases. D Schlossberg, ed. WB Saunders, Philadelphia, 2000. Mariuz P: Infection in HIV-Infected Patients. In: Toxoplasma-The Disease and Its Prevention, T Wreghitt and D Joynson, eds. Cambridge University Press, 1998. Markowitz M. Vesanen M. Tenner-Racz K. Cao Y. Binley JM. Talal A. Hurley A. Jin X. et al. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis 1999;179(3):527-37. Markowitz M. Jin X. Hurley A. Simon V. Ramratnam B. Louie M. Deschenes GR. et al. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis. 2002;186(5):634-43.
Marron RL, Lanphear BP, Kouides R, Dudman L, Manchester RA, Christy C. Efficacy of informational letters on hepatitis B immunization rates in university students. J Am Coll Health. 1998;47(3):123-7.
McCarthy CA. Hall CB. Respiratory syncytial virus: concerns and control. Pediatrics in Review. 2003;24(9):301-9. McElrath MJ. Corey L. Montefiori D. Wolff M. Schwartz D. Keefer M. et al. A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group. AIDS Res Human Retroviruses. 2000;16(9):907-19. Merle E. Rose RC. LeRoux L. Moroianu J. Nuclear import of HPV11 L1 capsid protein is mediated by karyopherin alpha2beta1 heterodimers. J Cellular Biochemistry 1999;74(4):628-37. Metzner KJ. Jin X. Lee FV. et al. Effects of in vivo CD8(+) T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Exp Med 2000;191(11):1921-31. Miller GE, Cohen S, Pressman S, Barkin A, Rabin B, Treanor JJ. Psychological stress and antibody response to influenza vaccination: when is the critical period for stress, and how does it get inside the body? Psychosom Med 2004;66:215-23. Miller MW, Luque AE, Battaglia LF, Mazza S, Everbach EC. Biological and environmental factors affecting ultrasound-induced hemolysis in vitro: 1. HIV macrocytosis (cell size). Ultrasound Med Biol. 2003;29(1):77-91. Miller TL, Mawn BE, Orav EJ, Wilk D, Weinberg GA, Nicchitta J, Furuta L, Cutroni R, McIntosh K, Burchett SK, Gorbach SL. The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children. Pediatrics. 2001;107(5):E77. Mora-Duarte J. Betts R. Rotstein C. Colombo AL. Thompson-Moya L. Smietana J. Lupinacci R. Sable C. Kartsonis N. Perfect J. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347(25):2020-9.
Morgan DJ, Vargas SL, Reyes-Mugica M, Walterspiel JN, Carver W, Gigliotti F. Identification of Pneumocystis carinii in the lungs of infants dying of sudden infant death syndrome. Pediatr Infect Dis J. 2001;20(3):306-9.
Morse GD. Reichman RC. Fischl MA. Para M. Leedom J. Powderly W. Demeter LM. et al. Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. Antiviral Res 2000;45(1):47-58. Morse GD. Cohn SE, Shelton MJ, Greisberger C., Cox SR, Della-Coletta AA, Freimuth WW, Reichman RC. Multiple-Dose Pharmacokinetics of Delavirdine Mesylate and Didanosine in HIV-Infected Patients. Clin Drug Inv 2003;23(5):323-328
Murata Y., and Falsey AR. RSV infection in elderly adults. In: Cane, P. (Ed.), Perspectives in Medical Virology: Respiratory Syncytial Viruses (Elsevier Life Sciences, London), 2006, in press
Nelson LM. Rose RC. Moroianu J. Nuclear import strategies of high risk HPV16 L1 major capsid protein. J Biological Chem. 2002;277(26):23958-64.
Nelson LM. Rose RC. Moroianu J. The L1 major capsid protein of human papillomavirus type 11 interacts with Kap beta2 and Kap beta3 nuclear import receptors. Virology. 2003;306(1):162-9. Neughebauer B. Alvarez V. Harb T. Keefer M. Constrictive pericarditis caused by candida glabrata in an immunocompetent patient: case report and review of literature. Scandinavian J Infect Dis. 2002;34(8):615-9.
Norton RA, Caserta MT, Hall CB, Schnabel K, Hocknell P, Dewhurst S. Detection of human herpesvirus 6 by reverse transcription-PCR. J Clin Microbiol. 1999;37(11):3672-5.
Ogg GS. Jin X. Bonhoeffer S. et al. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virology 1999;73(1):797-800. Ojukwu IC, Christy C. Rat-bite fever in children: case report and review. Scand J Infect Dis. 2002;34(6):474-7.
Ojukwu IC. Newton DW. Luque AE. Kotb MY. Menegus M. Invasive Group C Streptococcus infection associated with rhabdomyolysis and disseminated intravascular coagulation in a previously healthy adult. Scand J Infect Dis. 2003;33(3):227-9. Ortiz GM. Nixon DF. Trkola A. Binley J. Jin X. et al. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest. 1999;104(6):R13-8. Para MF. Meehan P. Holden-Wiltse J. Fischl M. Morse G. Shafer R. Demeter LM, et al. ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. Antimicrob Agents Chemother. 1999;43(6):1373-8. Passmore JA. Burch VC. Shephard EG. Marais DJ. Allan B. Kay P. Rose RC. Williamson AL. Single-cell cytokine analysis allows detection of cervical T-cell responses against human papillomavirus type 16 L1 in women infected with genital HPV. J Med Virol. 2002;67(2):234-40. Pichichero ME. Cernichiari E. Lopreiato J. Treanor J. Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study. Lancet 2002;360(9347):1737-41. Pichichero ME. Porcelli S. Treanor J. Anderson P. Serum antibody responses of weanling mice and two-year-old children to pneumococcal-type 6A-protein conjugate vaccines of differing saccharide chain lengths. Vaccine. 1998;16(1):83-91. Piedra PA. Yan L. Kotloff K. Zangwill K. Bernstein DI. King J. Treanor J. Munoz F. Wolff M. Cho I. Mendelman PM. Cordova J. Belshe RB. Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children. Pediatrics 2002;110(4):662-72. Renda MJ, Rosenblatt JD, Klimatcheva E, Demeter L, Bambara R, Planelles V. Mutation of the methylated tRNALys3 residue A58 disrupts reverse transcription and inhibits replication of human immunodeficiency virus type 1. J Virol 2001;75:9671-8. Rodrigo W.W.I.S, Jin X, Blackley SD, Rose RC and Schlesinger JJ. Differential Enhancement of Dengue Immune Complex Infectivity Mediated by Signaling-Competent and Signaling-Incompetent Human FcgRIA (CD64) or FcgRIIA (CD32). J Virol 80:10128, 2006
Rodrigues DS. Medeiros EA. Weckx LY. Bonnez W. Salomao R. Kallas EG. Immunophenotypic characterization of peripheral T lymphocytes in Mycobacterium tuberculosis infection and disease. Clin Experimental Immunol. 2002;128(1):149-54.
Rose RC. Lane C. Wilson S, et al. Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies. Vaccine 1999;17(17):2129-35. Rose RC. White WI. Li M. Suzich JA. Lane C. Garcea RL. Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. J Virology 1998;72(7):6151-4. Sasagawa T. Rose RC. Azar KK. Sakai A. Inoue M. Mucosal immunoglobulin-A and -G responses to oncogenic human papilloma virus capsids. International J Cancer. 2003;104(3):328-35.
Schaffer SJ, Szilagyi PG, Shone LP, Ambrose SJ, Dunn MK, Barth RD, Edwards K, Weinberg GA, Balter S, Schwartz B. Physician perspectives regarding pneumococcal conjugate vaccine. Pediatrics. 2002;110(6):e68.
Schlesinger JJ. Chapman SE. Influence of the human high-affinity IgG receptor FcgammaRI (CD64) on residual infectivity of neutralized dengue virus. Virology 1999;260(1):84-8. Schur CL. Berk ML. Dunbar JR. Shapiro MF. Cohn SE. Bozzette SA. Where to seek care: an examination of people in rural areas with HIV/AIDS. Journal of Rural Health. 2002;18(2):337-47. Shelly MA. Pichichero ME. Treanor JJ. Low baseline antibody level to diphtheria is associated with poor response to conjugated pneumococcal vaccine in adults. Scand J Infect Dis. 2001;33(7):542-4. Sheon AR. Wagner L. McElrath MJ. Keefer MC, et al. Preventing discrimination against volunteers in prophylactic HIV vaccine trials: lessons from a phase II trial. J AIDS 1998;19(5):519-26. Shiramizu B. Theodore D. Bassett R. Coel M. Sherman KE. Glesby MJ. Chow D. Alston B. Colquhoun D. Merigan TC Jr. Reichman RC. Berggren R. Burning WJ. Brobst S. Correlation of single photon emission computed tomography parameters as a noninvasive alternative to liver biopsies in assessing liver involvement in the setting of HIV and hepatitis C virus coinfection: a multicenter trial of the Adult AIDS Clinical Trials Group. J Acquired Imm Defic Syndr: JAIDS. 2003;33(3):329-35. Singh S, Barghoorn J, Bagdonas A, Adler J, Treanor J, Kinnersley N, Ward P. Clinical benefits with oseltamivir in treating influenza in adult populations. Clin Drug Invest 2003;23:561-9. Sloand JA, Shelly MA, Brien JM, Schiff MJ, Dhakal MP. Success of prolonged hibernation of subcutaneously-placed peritoneal dialysis catheters. Perit Dial Int. 2001;21(6):617-9. Sloand JA, Shelly MA, Feigin A, Bernstein P, Monk RD. A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis. 2004;43(4):663-70.
Synder-Cappione JE, Divekar AA, Maupin GM, Jin X, Demeter LM, Mosmann TR. HIV-specific cytotoxic cell frequencies measured directly ex vivo by the Lysispot assay can be higher or lower than the frequencies of interferon gamma-secreting cells: anti-HIV cytotoxicity is not generally impaired relative to other chronic virus responses. J Immunology. 2006, 176 (4): 2662-8.
Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hammer SM, Kubin CJ. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother. 2004;54(2):566-9. Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med. 2000;154(1):55-61. Suh K. Mariuz P: Gastrointestinal Histoplasmosis in patients with AIDS: case report and review of the literature. Clin Infect Dis 2001;32:483-91. Tabechian D, Pattanaik D, Suresh U, Cohn SE, Nadasdy T. Lupus-like Nephritis in a HIV positive patient: report of a case and review of the literature. Clin Nephrol 2003;60(3):187-94 Tasker SA. O'Brien WA. Treanor JJ, et al. Effects of influenza vaccination in HIV-infected adults: a double-blind, placebo-controlled trial. Vaccine 1998;16(9-10):1039-42. Tasker SA. Treanor JJ. Paxton WB. Wallace MR. Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999;131(6):430-3. Tong N. Perry SW. Zhang Q. James HJ. Guo H. Brooks A. Bal H. Kinnear SA. Fine S, et al. Neuronal fractalkine expression in HIV-1 encephalitis: roles for macrophage recruitment and neuroprotection in the central nervous system. J Immunol 2000;164(3):1333-9. Treanor J, Wright PF. Immune correlates of protection against influenza in the human challenge model. Developments in Biologicals 2003;115:97-105. Treanor J. Falsey A. Respiratory viral infections in the elderly. Antiviral Res 1999;44(2):79-102. Treanor J. Keitel W. Belshe R. Campbell J. Schiff G. Zangwill K. Wolff M. Klimov A. Levandowski R. Lambert L. Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. Vaccine. 2002;20(7-8):1099-105. Treanor J. Influenza vaccine- outmaneuvering shift and drift. N Engl J Med 2004;350(3):218-20. Treanor JJ. Betts RF. Evaluation of live, cold-adapted influenza A and B virus vaccines in elderly and high-risk subjects. Vaccine 1998;16(18):1756-60. Treanor JJ. Hayden FG. Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000;283(8):1016-24. Treanor JJ. Kotloff K. Betts RF, et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 1999;18(9-10):899-906. Treanor JJ. Wilkinson BE. Masseoud F. et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001;19(13-14):1732-7. Vedhara K, McDermott M, Evans TG, Treanor JJ, Plummer S, Tallon D, Cruttenden KA, Schiffitto G. Chronic caregive stress in non-elderly caregivers: psychological, endocrine, and immune implications. J Psychosomatic Res 2002;53:1153-61.
von Reyn CF, Williams PL, Lederman HM, McCutchan JA, Koletar SL, Murphy RL, Cohn SE, et al. Skin test reactivity and cellular immune responses to Mycobacterium avium sensitin in AIDS patients at risk for disseminated M. avium infection. Clin Diagn Lab Immunol. 2001;8(6):1277-8. Wailker BD, Rosenberg ES, Hay CM, Basgoz N, Yang OO. Immune control of HIV-1 replication. Adv Exp Med Biol. 1998;452:159-67.
Walsh E, Falsey AR. Age Related Differences in Humoral Immune Responseto Respiratory Syncytial Virus Infection in Adults. J Med Virol. 2004;73:295-9. Walsh E, Falsey AR. Humoral and Mucosal Immunity in Protection fromNatural Respiratory Syncytial Virus Infection in Adults. J Infect Dis 2004; 190:373-8. Walsh EE, Cox C, Falsey AR. Clinical features of influenza A virusinfection in elderly hospitalized persons. J Amer Geriatr Soc 2002;50:1498-1503.
Walsh EE, Falsey AR, Swinburne IA, Formica MA. Reverse Transcription Polymerase Chain Reaction (RT-PCR) for Diagnosis of Respiratory Syncytial Virus Infection in Adults: Use of a Single Tube "Hanging Droplet" Nested PCR. J Med Virol; 2001;63(3):259-263. Walsh EE, Peterson DR, Falsey AR. Risk factors for severe respiratory syncytial virus infection in elderly persons. J Infect Dis 2004;189:233-8. Walsh EE. Falsey AR. A simple and reproducible method for collecting nasal secretions in frail elderly adults, for measurement of virus-specific IgA. J Infect Dis 1999;179(5):1268-73. Walsh EE. Falsey AR. Hennessey PA. Respiratory syncytial and other virus infections in persons with chronic cardiopulmonary disease. Amer J Respiratory Crit Care Med 1999;160(3):791-5. Walsh EE. Falsey AR. Sullender WM. Monoclonal antibody neutralization escape mutants of respiratory syncytial virus with unique alterations in the attachment (G) protein. J General Virology 1998;79 ( Pt 3):479-87. Wang X, Messerle M, Sapinoro R, Santos K, Hocknell PK, Jin X, Dewhurst S. Murine cytomegalovirus abortively infects human dendritic cells, leading to expression and presentation of virally vectored genes. J Virol. 2003;77(13):7182-92. Wang YK, Das B, Huber DH, Wellington M, Kabir MA, Sherman F, Rustchenko E. Role of the 14-3-3 protein in carbon metabolism of the pathogenic yeast Candida albicans. Yeast. 2004;21(8):685-702. Warzecha H. Mason HS. Lane C. Tryggvesson A. Rybicki E. Williamson AL. Clements JD. Rose RC. Oral immunogenicity of human papillomavirus-like particles expressed in potato. J Virology. 2003;77(16):8702-11. Weinberg GA, Erdman DD, Edwards KM, Hall CB, Walker FJ, Griffin MR, Schwartz B; New Vaccine Surveillance Network Study Group. Superiority of reverse-transcription polymerase chain reaction to conventional viral culture in the diagnosis of acute respiratory tract infections in children. J Infect Dis. 2004;189(4):706-10. Weinberg GA. Laboratory diagnosis of ehrlichiosis and babesiosis. Pediatr Infect Dis J. 2001;20(4):435-7. Weinberg GA. Postexposure prophylaxis against human immunodeficiency virus infection after sexual assault. Ped Infect Dis J. 2002;21(10):959-60.
Weinberg GA, Luque AE, Brown ST. Nonoccupational HIV postexposure prophylaxis. JAMA. 2005;294(13):1615.
Wellington M, Bliss JM, Haidaris CG. Enhanced phagocytosis of Candida species mediated by opsonization with a recombinant human antibody single-chain variable fragment. Infect Immun. 2003;71(12):7228-31.
Wellington M. Gigliotti F. Update on antifungal agents. Ped Infect Dis J. 2001;20(10):993-5.
Wells J, Gigliotti F, Simpson-Haidaris PJ, Haidaris CG. Epitope mapping of a protective monoclonal antibody against Pneumocystis carinii with shared reactivity to Streptococcus pneumoniae surface antigen PspA. Infect Immun. 2004;72(3):1548-56.
White WI. Wilson SD. Bonnez W. Rose RC. Koenig S. Suzich JA. In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J Virology 1998;72(2):959-64. Woerle HJ, Mariuz PR, Meyer C, Reichman RC, Popa EM, Dostou JM, Welle SL, Gerich JE. Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes 2003;52(4):918-25. Wright PF, Mestecky J, McElrath MJ, Keefer MC, Gorse GJ, Goepfert PA, Moldoveanu Z, Schwartz D, Spearman PW, El Habib R, Spring MD, Zhu Y, Smith C, Flores J, Weinhold KJ; National Institutes of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein. J Infect Dis. 2004;189(7):1221-31 Wright PF. Lambert JS. Gorse GJ. Hsieh RH. McElrath MJ. Weinhold K. Wara DW. Anderson EL. Keefer MC, et al. Immunization with envelope MN rgp120 vaccine in human immunodeficiency virus-infected pregnant women. J Infect Dis 1999;180(4):1080-8. Wright TW, Notter RH, Wang Z, Harmsen AG, Gigliotti F. Pulmonary inflammation disrupts surfactant function during Pneumocystis carinii pneumonia. Infect Immun. 2001;69(2):758-64. Wright TW, Pryhuber GS, Chess PR, Wang Z, Notter RH, Gigliotti F. TNF receptor signaling contributes to chemokine secretion, inflammation, and respiratory deficits during Pneumocystis pneumonia. J Immunol. 2004;172(4):2511-21. Wurapa AK. Luque AE. Menegus MA. Oral hairy leukoplakia: a manifestation of primary infection with Epstein-Barr virus? Scand J Infect Dis 1999;31(5):505-6.
Wyman P, Moynihan J, Shirley Eberly, Christopher Cox, Wendi Cross, Christina Yoo, Gladys Lathan, Philip Ng, Jin X, and Caserta MT. Natural Killer Cell Activity and the Frequency of Illnesses Associated with Family Stress. Arch Pediatrics Adolescent Medicine 2006: (in press)
Yu DT, Platt R, Lanken PN, Black E, Sands KE, Schwartz JS, Hibberd PL, Graman PS, Kahn KL, Snydman DR, Parsonnet J, Moore R, Bates DW; AMCC Sepsis Project Working Group Relationship of pulmonary artery catheter use to mortality and resource utilization in patients with severe sepsis. Crit Care Med 2003;31(12):2734-41.
Yu DT. Black E. Sands KE. Schwartz JS. Hibberd PL. Graman PS. Lanken PN. Kahn KL. Snydman DR. Parsonnet J. Moore R. Platt R. Bates DW. Severe sepsis: variation in resource and therapeutic modality use among academic centers. Critical Care (London). 2003;7(3):R24-34.
Yu J, Chen H, Horton H, Bansal A, McElrath J, Reichman R, Goepfert P, Jin X. Interleukin-2 Reconstitutes Defective Human Immunodeficiency Virus (HIV) - and Cytomegalovirus (CMV) - Specific CD8+ T Cell Proliferation in HIV Infection. J Medical Virology 2006, 78:1147-1157.
November 2006 |